<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274335</url>
  </required_header>
  <id_info>
    <org_study_id>2020-KEP-401</org_study_id>
    <nct_id>NCT04274335</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of Tranexamic Acid in Women Having Caesarean Section Birth [WOMAN-PharmacoTXA]</brief_title>
  <official_title>A Randomised Controlled Trial to Assess the Pharmacokinetics and Pharmacodynamics of Intramuscular, Intravenous and Oral Administration of Tranexamic Acid in Women Giving Birth by Caesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rawalpindi Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intramuscular injection and oral solution of tranexamic acid (TXA) would increase its use in
      situations where administration of intravenous drugs is difficult. The investigators aim to
      assess the population pharmacokinetics (PK) and pharmacodynamics (PD) of intravenous,
      intramuscular and oral TXA in women undergoing undergoing caesarean section (CS) with at
      least one known risk factor for postpartum haemorrhage (PPH)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, randomised controlled trial to assess the pharmacokinetics and
      pharmacodynamics of intramuscular, intravenous and oral solution administration of tranexamic
      acid in women giving birth by caesarean section. 120 women (30 receiving oral liquid, 30
      receiving intramuscular, 30 receiving intravenous and 30 receiving no TXA who have at least 6
      evaluable PK samples will be randomised.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic</measure>
    <time_frame>24 hours after randomisation</time_frame>
    <description>Concentration of TXA in Maternal blood over time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Placenta transfer of TXA</measure>
    <time_frame>at birth of baby</time_frame>
    <description>Concentrations of TXA in placenta cord blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placenta transfer of TXA</measure>
    <time_frame>within 24 hours of birth</time_frame>
    <description>Concentration of neonate TXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of D-dimer</measure>
    <time_frame>up to 24 hours after randomisation</time_frame>
    <description>Maternal blood concentration over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal blood volume lost</measure>
    <time_frame>from incision to 2 hours from CS</time_frame>
    <description>total blood loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of Injection site reaction from IM administration</measure>
    <time_frame>from randomisation up to 7 days after</time_frame>
    <description>Local reactions at injection site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse events (maternal and neonate)</measure>
    <time_frame>from randomisation up to 7 days after</time_frame>
    <description>any untoward medical events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of women with a clinical diagnosis of PPH</measure>
    <time_frame>up to 24 hours after giving birth</time_frame>
    <description>total blood loss of &gt;1000 mL or any blood loss sufficient to cause haemodynamic instability or requires treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pregnancy, High Risk</condition>
  <arm_group>
    <arm_group_label>Intravenous tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral liquid tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No tranexamic acid</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid 100Mg/Ml Inj Vil 10Ml</intervention_name>
    <description>1 gram of tranexamic acid to be administered intravenously</description>
    <arm_group_label>Intravenous tranexamic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid Oral Solution</intervention_name>
    <description>4 grams of tranexamic acid given as an oral solution</description>
    <arm_group_label>Oral liquid tranexamic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid Injectable Product</intervention_name>
    <description>1 gram of tranexamic acid given as 2 separate intramuscular injection</description>
    <arm_group_label>Intramuscular tranexamic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women admitted to hospital giving birth by CS

          -  History of at least one risk factor for PPH

          -  Adult (â‰¥18 years old)

        Exclusion Criteria:

          -  Women giving birth vaginally

          -  Women with a known allergy to TXA or its excipients

          -  Women with current antepartum haemorrhage

          -  Women known to have received TXA within 48 hours prior to randomisation

          -  Women with known renal impairment

          -  Women with any known blood clotting disorder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women giving birth by caesarean section</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haleema Shakur-Still</last_name>
    <role>Study Chair</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian Roberts</last_name>
    <role>Study Chair</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haleema Shakur-Still</last_name>
    <phone>+44 207 958 8113</phone>
    <email>Haleema.Shakur@lshtm.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rawalpindi Medical University</name>
      <address>
        <city>Rawalpindi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Totally anonymised dataset used for main analysis will be made freely available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>freely available 1 year after main publication</ipd_time_frame>
    <ipd_access_criteria>Free login to website required for monitoring usage of data</ipd_access_criteria>
    <ipd_url>https://freebird.lshtm.ac.uk</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

